Filing Coverage: Fluidigm Corp Has Another Bullish Trade, John A. Levin’s Levin Capital Strategies Bought Stake!

Filing Coverage: Fluidigm Corp Has Another Bullish Trade, John A. Levin's Levin Capital Strategies Bought Stake!

The New John A. Levin’s Levin Capital Strategies Holding in Fluidigm Corp

Levin Capital Strategies filed with the SEC SC 13D form for Fluidigm Corp. The form can be accessed here: 000092189516005864. As reported in John A. Levin’s Levin Capital Strategies’s form, the filler as of late owns 25.2% or 7,317,390 shares of the Health Care–company.

Fluidigm Corp stake is a new one for the for the hedge fund and it was filed because of activity on October 13, 2016. We feel this shows John A. Levin’s Levin Capital Strategies’s positive view for the stock. For a hedge fund managing $8.28 billion in assets and having 31+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.

The hedge fund is active investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of John A. Levin’s Levin Capital Strategies’s US equities portfolio is in this sector.

Reasons Why John A. Levin’s Levin Capital Strategies Bought – Fluidigm Corp Stock

PURPOSE OF TRANSACTION

.

The Reporting Persons purchased the Shares based on the Reporting Persons’ belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity.The Reporting Persons remain passive investors in the Issuer and are filing the Schedule 13D as a result of acquiring over 20% of the outstanding Shares of the Issuer. The Reporting Persons have not acquired the Shares with a purpose or effect of changing or influencing control of the Issuer and no Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D. The Reporting Persons may acquire or dispose of Shares in the future.

Fluidigm Corp Institutional Sentiment

Latest Security and Exchange filings show 103 investors own Fluidigm Corp. The institutional ownership in Q3 2015 is high, at 128.40% of the outstanding shares. This is increased by 6479150 the total institutional shares. 37288715 were the shares owned by these institutional investors. In total 23 funds opened new Fluidigm Corp stakes, 35 increased stakes. There were 21 that closed positions and 34 reduced them.

Opus Point Partners Management Llc is an institutional investor bullish on Fluidigm Corp, owning 15000 shares as of Q3 2015 for 0.07% of its portfolio. Fic Capital Inc owns 188700 shares or 0.72% of its portfolio. CA Endurant Capital Management Lp have 1.35% of their stock portfolio for 497768 shares. Further, Senzar Asset Management Llc reported stake worth less than 0.01% of its US stock portfolio. The IL High Pointe Capital Management Llc owns 18000 shares. Fluidigm Corp is 0.07% of the manager’s US portfolio.

Business Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment decreased to 0.82 in Q2 2016. Its down 0.14, from 0.96 in 2016Q1. The ratio dived, as 14 funds sold all Fluidigm Corporation shares owned while 31 reduced positions. 8 funds bought stakes while 29 increased positions. They now own 25.56 million shares or 9.86% less from 28.35 million shares in 2016Q1.

Financial Bank Of America Corporation De has 0% invested in the company for 2,378 shares. Alliancebernstein L P has invested 0% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM). Iguana Healthcare Mgmt Llc, a New York-based fund reported 50,000 shares. Manufacturers Life Insurance The holds 0% or 22,238 shares in its portfolio. Metropolitan Life Insurance Com Ny last reported 20,157 shares in the company. California State Teachers Retirement System reported 60,987 shares or 0% of all its holdings. Neuberger Berman Grp Ltd Llc last reported 926,340 shares in the company. Orbimed Advsr Ltd Co, a New York-based fund reported 1.75 million shares. Walleye Trading Llc has 1,368 shares for 0% of their US portfolio. Engineers Gate Manager Ltd Partnership has 17,877 shares for 0.01% of their US portfolio. Blackrock Advsr Ltd Liability Corporation accumulated 14,529 shares or 0% of the stock. Panagora Asset Mgmt has invested 0% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM). New York State Common Retirement Fund holds 38,475 shares or 0% of its portfolio. Amer Intl Grp Inc Inc, a New York-based fund reported 16,739 shares. Principal Financial Inc holds 0% or 77,393 shares in its portfolio.

Analysts await Fluidigm Corporation (NASDAQ:FLDM) to report earnings on November, 3. They expect $-0.54 EPS, down 80.00% or $0.24 from last year’s $-0.3 per share. After $-0.47 actual EPS reported by Fluidigm Corporation for the previous quarter, Wall Street now forecasts 14.89% negative EPS growth.

The stock decreased 3.97% or $0.19 during the last trading session, hitting $4.47. About 675,411 shares traded hands or 179.12% up from the average. Fluidigm Corporation (NASDAQ:FLDM) has declined 39.40% since March 11, 2016 and is downtrending. It has underperformed by 44.86% the S&P500.

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The company has a market cap of $85.70 million. The Firm operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. It currently has negative earnings. The Company’s products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits , and assays and reagents.

Fluidigm Corporation (NASDAQ:FLDM) Ratings Coverage

Out of 5 analysts covering Fluidigm (NASDAQ:FLDM), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. $28 is the highest target while $8 is the lowest. The $14.71 average target is 229.08% above today’s ($4.47) stock price. Fluidigm has been the topic of 17 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Mizuho maintained it with “Neutral” rating and $8 target price in Friday, October 30 report. As per Friday, August 7, the company rating was maintained by Mizuho. Deutsche Bank initiated Fluidigm Corporation (NASDAQ:FLDM) on Thursday, January 7 with “Buy” rating. Mizuho maintained Fluidigm Corporation (NASDAQ:FLDM) on Friday, August 5 with “Buy” rating. Piper Jaffray downgraded the stock to “Neutral” rating in Friday, August 7 report. The company was upgraded on Friday, October 30 by Cantor Fitzgerald. Zacks upgraded the stock to “Sell” rating in Friday, August 21 report. On Friday, August 5 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Hold” rating by Mizuho on Sunday, August 9. Maxim Group maintained it with “Hold” rating and $15 target price in Thursday, August 27 report.

More notable recent Fluidigm Corporation (NASDAQ:FLDM) news were published by: Schaeffersresearch.com which released: “Analyst Downgrades: Fluidigm Corporation, Netflix, Inc., and Nokia Corp” on October 13, 2016, also Fool.com with their article: “Why Fluidigm Corporation is Soaring Higher” published on October 30, 2015, Benzinga.com published: “15 Biggest Mid-Day Losers For Thursday” on October 13, 2016. More interesting news about Fluidigm Corporation (NASDAQ:FLDM) were released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: Lindsay Gains Following Q4 Results; Fluidigm …” published on October 13, 2016 as well as Fool.com‘s news article titled: “Why Shares in Fluidigm Corporation Are Bursting” with publication date: May 08, 2015.

According to Zacks Investment Research, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California.”

FLDM Company Profile

Fluidigm Corporation, incorporated on March 29, 2007, creates, makes and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Firm sells instruments and consumables, including integrated fluidic circuits, assays and reagents, to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies. The Firm operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. The Firm offers various types of products, which include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment